Adenovirus News and Research

RSS

Adenoviruses most commonly cause respiratory illness; however, depending on the infecting serotype, they may also cause various other illnesses, such as gastroenteritis, conjunctivitis, cystitis, and rash illness. Symptoms of respiratory illness caused by adenovirus infection range from the common cold syndrome to pneumonia, croup, and bronchitis. Patients with compromised immune systems are especially susceptible to severe complications of adenovirus infection. Acute respiratory disease (ARD), first recognized among military recruits during World War II, can be caused by adenovirus infections during conditions of crowding and stress.

Researchers identify adenovirus gene therapy for placental insufficiency

A new study identified an adenovirus gene therapy vector carrying a VEGF isoform. It can improve uterine blood flow in placental insufficiency, as reported in the peer-reviewed journal Human Gene Therapy.

15 Dec 2020

Interim results show Oxford COVID-19 vaccine protects against symptomatic disease

First full results from interim analysis confirm that the Oxford COVID-19 vaccine (AZD1222) has an acceptable safety profile and is efficacious against symptomatic COVID-19 disease, with no hospitalizations or severe disease reported in the COVID-19 vaccine group so far.

9 Dec 2020

The intranasal route of immunization may offer effective protection against SARS-CoV-2

Researchers at the School of Medicine, Washington University in Saint Louis, USA, showed that the intranasal route of immunization could provide a more efficient protection against SARS-CoV-2 compared to the intramuscular route (i.e. through ‘jabs’).

7 Dec 2020

Oxford University and AstraZeneca release their COVID-19 vaccine results

AstraZeneca and the University of Oxford have just released their results from its interim analysis of AZD1222, a vaccine being trialed to prevent COVID-19.

From AstraZeneca 23 Nov 2020

UK’s COVID-19 vaccine shows similar safety and immunogenicity results in healthy older adults

The UK's vaccine against SARS-CoV-2 shows similar safety and immunogenicity results in healthy older adults (aged 56 years and over) to those seen in adults aged 18-55 years.

19 Nov 2020

New understanding of glycan signatures of the SARS-COV-2 S1 spike protein

A team of scientists from the University of Oxford, UK, has revealed that site-specific glycosylation differs between spike proteins derived from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and a viral vector-based vaccine candidate.

18 Nov 2020

Researchers use machine learning algorithm to identify common respiratory pathogens

The ongoing global pandemic has created an urgent need for rapid tests that can diagnose the presence of the SARS-CoV-2 virus, the pathogen that causes COVID-19, and distinguish it from other respiratory viruses.

11 Nov 2020

VA joins Pentagon in recruiting volunteers for COVID vaccine trials

The Department of Veterans Affairs is recruiting 8,000 volunteers for the Phase 3 clinical trials of at least four COVID-19 vaccine candidates at 20 federal medical facilities across the U.S., according to officials with the VA and Operation Warp Speed, the Trump administration's initiative to fast-track a coronavirus vaccine.

6 Nov 2020

Green tea and some fruit juices inhibit SARS-CoV-2 in vitro

Green tea, chokeberry juice, and pomegranate juice killed flu and SARS-CoV-2 viruses when incubated with the viruses in vitro. Thus, oral rinsing using these might be effective in preventing COVID-19.

5 Nov 2020

Booster dose enhances immunogenicity of ChAdOx1 SARS-CoV-2 vaccine in aged mice

Now, a new study published on the pre-print server bioRxiv* shows that a single dose of the vaccine has induced cellular and humoral immunity in aged or older mice. A second dosage was needed to enhance the vaccine's immune response, showing that a prime-boost strategy may be an essential step to boost immunogenicity in the elderly.

30 Oct 2020

UH and CWRU announce Phase 3 trial of Astrazeneca's investigational COVID-19 vaccine

University Hospitals and Case Western Reserve University announced today that UH Cleveland Medical Center has been selected as a clinical trial site for the Phase 3 global study of an investigational vaccine against SARS-CoV-2, sponsored by AstraZeneca.

29 Oct 2020

Phase 1 trial results of gorilla adenovirus vaccine for COVID-19

A recent study published on the preprint server bioRxiv* in October 2020 reports the development of a novel vaccine based on a simian adenoviral vector obtained from a group C gorilla isolate called GRAd32. This could help speed up vaccine development.

26 Oct 2020

Scientists uncover important disease-fighting role for cells in the liver

Scientists at Scripps Research have uncovered an important disease-fighting role for cells called hepatocytes, which constitute most of the liver. The discovery could potentially be harnessed to develop new medicines for viral illnesses.

19 Oct 2020

The COVID-19 vaccine pipeline

Researchers from Mayo Clinic, United States of America, have reviewed the immunity developed against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes COVID-19 disease.

14 Oct 2020

COVID-19 vaccine candidate shows potent immune response

A COVID-19 vaccine candidate that underwent extensive preclinical testing at the University of Alabama at Birmingham this spring and summer shows potent preclinical immune responses -; including several that distinguish it from other COVID-19 vaccine approaches -; according to a preprint deposited in the BioRxiv repository this week.

13 Oct 2020

Nasal spray COVID-19 vaccine shows promising results in mice

With promising vaccines comes a new candidate that has shown potent pre-clinical immune responses. The vaccine, developed by scientists at the University of Alabama at Birmingham (UAB), induced a potent T-cell response at the mucus layer of the lungs, including killer CD8+ T-cells, which can recognize and kill virally infected cells.

12 Oct 2020

Researchers hope to develop an effective COVID-19 vaccine using bovine adenovirus

A researcher in Penn State's College of Agricultural Sciences is part of a team of scientists working to develop a unique COVID-19 vaccine that uses a bovine adenovirus as a safe and effective delivery vehicle.

7 Oct 2020

J&J's COVID-19 vaccine shows potent immune response in phase 2 human trial

A multicenter phase 1/2a randomized, double-blinded, placebo-controlled clinical trial has been conducted recently to evaluate the safety, reactogenicity, and immunogenicity of a non-replicating adenovirus-based vaccine, namely Ad26.COV2.S against severe acute respiratory coronavirus 2 (SARS-CoV-2) infection.

28 Sep 2020

BIOCAD to produce liquid vaccine for COVID-19 treatment

Clinical trials of the vaccine are currently underway. The &laquoSputnik V» is the two-component vaccine. Revaccination is carried out at intervals of 3-4 weeks. Moreover, with the repeated introduction of a particle of coronavirus RNA, it is covered with a new adenovirus.

25 Sep 2020

Research says in SARS-CoV-2 canine infection, transmission unlikely

A new study published on the preprint server bioRxiv* in September 2020 shows that pet dogs have been falling sick and dying of a mysterious respiratory infection, often showing the presence of anti- severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies, even though in many cases they do not test positive for COVID-19.

24 Sep 2020